ClinicalTrials.gg
Not yet recruitingNCT07770672Updated Aug 18, 2026

An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on 68Ga-FAPI ([68Ga] Fibroblast Activation Protein Inhibitor)/¹⁸F-FDG (2-Deoxy-2-[¹⁸F]Fluoro-D-glucose) Dual Imaging

A Phase 2 interventional study of Retlirafusp Alfa Plus Chemotherapy and Adebrelimab Plus Chemotherapy in Esophageal Cancer and ESCC, sponsored by Tan Lijie. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Tan Lijie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
185th of 394
92 · median 80
Started
2026
with 30 others
Phase 2
146 of 502
72 open now
Primary completion
2029-03
later than 225 of 237 live
Registered
494th of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 185th largest by planned enrollment of the 394 interventional ones that give a count, is one of 31 that started in 2026, is one of 146 in phase 2, reaches primary completion later than 225 of the 237 other live ones, and was the 494th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate whether two positron emission tomography/computed tomography (PET/CT) scans performed before treatment-68Ga-FAPI and 18F-FDG-can help predict how well patients with resectable, locally advanced thoracic esophageal squamous cell carcinoma respond to immunotherapy plus chemotherapy given before surgery. The study hypothesis is that information from the two scans can identify patients who are unlikely to have a pathologic complete response (pCR), meaning no remaining cancer in the removed esophagus or lymph nodes, and that retlirafusp alfa may improve pathologic response compared with adebrelimab when each is combined with chemotherapy in these patients.

This study has two stages and plans to enroll 92 adults aged 18 to 75 years with previously untreated, stage II to IVA, resectable thoracic esophageal squamous cell carcinoma. All participants will undergo both PET/CT scans before treatment.

03

Conditions studied

  • Esophageal Cancer
  • ESCC

Keywords

  • PET-CT
  • ESCC
  • Neoadjuvant therapy
  • Adebrelimab (SHR-1316)
  • Retlirafusp alfa (SHR-1701)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for enrollment:

  1. Voluntarily agree to participate in the study and provide written .
  2. or cytologically confirmed esophageal squamous cell carcinoma.
  3. Thoracic esophageal cancer assessed by computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography/computed tomography (PET/CT), or other appropriate imaging, with clinical stage II to IVA disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system.
  4. Considered by a surgeon to be suitable for an R0 resection and planned to undergo surgery after completing treatment.
  5. Undergo both 18F-FDG and 68Ga-FAPI PET/CT imaging at baseline. For Stage 2, the participant's 18F-FDG and 68Ga-FAPI PET/CT parameters must meet the criteria of the prediction model for lack of pathologic complete response (non-pCR).
  6. Aged 18 to 75 years, inclusive, with no restriction based on sex.
  7. performance status (ECOG PS) of 0 or 1.
  8. No previous antitumor treatment for esophageal cancer, including radiotherapy, chemotherapy, surgery, or other antitumor treatment.
  9. No to surgery.
  10. Adequate major organ function, as defined by all of the following:

    1. Hematologic function. No blood components, hematopoietic growth factors, leukocyte-elevating agents, -elevating agents, or medications used to correct anemia are permitted within 14 days before the first administration of study treatment:

      • ≥1.5 × 10\^9/L;
      • Platelet count ≥100 × 10\^9/L;
      • ≥90 g/L.
    2. Biochemical function:

      • Total ≤1.5 × the (ULN);
      • (ALT) ≤2.5 × ULN and aspartate aminotransferase (AST) ≤2.5 × ULN;
      • Serum creatinine ≤1.5 × ULN or ≥50 mL/min, calculated using the Cockcroft-Gault formula.
    3. Coagulation function:

      • (INR) ≤1.5 × ULN;
      • Activated partial thromboplastin time (aPTT) ≤1.5 × ULN.
    4. Pulmonary function:

      • (FEV1) ≥1.2 L;
      • FEV1 percentage of predicted value (FEV1%) ≥50%;
      • Diffusing capacity of the lung for carbon monoxide (DLCO) ≥50%.
  11. A female participant of must have a negative serum pregnancy test within 72 hours before the first administration of study treatment, must not be breastfeeding, and must agree to use a highly effective method of with an annual failure rate of less than 1%, such as an intrauterine device, oral contraceptive, or condom, throughout the study and until 2 months after the last dose of adebrelimab or 6 months after the last dose of chemotherapy, whichever is longer. A male participant with a female partner of childbearing potential must be surgically sterile or agree to use an effective method of contraception throughout the study and until 2 months after the last dose of adebrelimab or 3 months after the last dose of chemotherapy, whichever is longer. Sperm donation is not permitted during the study.
  12. Able and willing to comply with the study procedures and follow-up requirements.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  1. Obvious invasion by the tumor or involved lymph nodes into organs adjacent to the esophageal lesion, including the pleura, pericardium, azygos vein, diaphragm, peritoneum, major arteries, vertebral body, or trachea.
  2. Supraclavicular lymph node .
  3. Diagnosis of another malignant tumor within 5 years before the first administration of study treatment, except for a with a low risk of metastasis or death and an expected 5-year survival rate greater than 90%. Participants with adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, or a similar malignancy may be considered eligible.
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
  5. Poor nutritional status, defined as a (BMI) of less than 18.5 kg/m2. A participant whose nutritional status is corrected through appropriate nutritional support before the initiation of treatment may still be considered eligible following assessment by the principal investigator.
  6. History of an allergic reaction to a monoclonal antibody.
  7. Receipt of any tumor-directed radiotherapy, chemotherapy, or other antitumor medication.
  8. Use of medication or systemic treatment for an immunosuppressive purpose within 2 weeks before the first administration of study treatment at a dose greater than 10 mg/day of prednisone or an equivalent dose. In the absence of an active disease, inhaled or topical corticosteroids and adrenal corticosteroid replacement at a dose greater than 10 mg/day of prednisone or an equivalent dose are permitted.
  9. Receipt of a within 4 weeks before the first administration of study treatment.
  10. Major surgery or severe trauma within 4 weeks before the first administration of study treatment.
  11. Any active autoimmune disease or history of an autoimmune disease, including but not limited to interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, or hypothyroidism. Participants with hypothyroidism may be considered eligible after hormone replacement therapy. Participants with psoriasis or childhood asthma or allergy that has completely resolved and requires no intervention during adulthood may be considered eligible; however, participants requiring medical intervention with a bronchodilator are not eligible.
  12. History of immunodeficiency, including a positive (HIV) test, another acquired or congenital immunodeficiency disorder, a history of organ transplantation, or a history of bone marrow transplantation.
  13. Poorly controlled cardiac symptoms or disease, including but not limited to:

    • (NYHA) class II or higher heart failure;
    • Unstable angina;
    • Myocardial infarction within the previous year;
    • supraventricular or ventricular arrhythmia that has not received appropriate clinical intervention or remains poorly controlled after clinical intervention.
  14. A serious infection of greater than Grade 2 according to the (CTCAE) within 4 weeks before the first administration of study treatment, including severe pneumonia requiring hospitalization, bacteremia, or other serious infectious complications; evidence of active pulmonary inflammation on baseline chest imaging; signs or symptoms of infection within 14 days before the first administration of study treatment; or a requirement for oral or intravenous antibiotic treatment within that period. Prophylactic antibiotic use is permitted.
  15. Active tuberculosis identified through medical history or CT examination; a history of active tuberculosis within 1 year before enrollment; or a history of active tuberculosis more than 1 year before enrollment without having received appropriate standard treatment.
  16. Active , defined as hepatitis B virus DNA ≥2,000 IU/mL or ≥10\^4 copies/mL; or , defined as a positive hepatitis C virus antibody test together with hepatitis C virus RNA above the lower limit of detection of the assay.
  17. Pregnant or breastfeeding female participants.
  18. Any other factor that, in the investigator's judgment, may result in forced premature discontinuation from the study, including another serious illness requiring concomitant treatment, including a psychiatric disorder; alcohol abuse; drug abuse; or family or social circumstances that may affect the participant's safety or compliance.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    Retlirafusp Alfa Plus Chemotherapy

    Drug: Retlirafusp Alfa Plus Chemotherapy

  • Active comparator
    Adebrelimab Plus Chemotherapy

    Drug: Adebrelimab Plus Chemotherapy

Interventions

  • DrugRetlirafusp Alfa Plus Chemotherapy

    Drug page: SHR-1701

    participants predicted by the 68Ga-FAPI/18F-FDG dual-imaging model to be unlikely to achieve a pathologic complete response will be randomly assigned to receive retlirafusp alfa in combination with nab-paclitaxel and cisplatin of each 3-week cycle for 2 cycles. Participants without a contraindication to surgery will undergo esophagectomy 4 to 6 weeks after the last treatment dose.

  • DrugAdebrelimab Plus Chemotherapy

    Drug page: Adebrelimab

    participants predicted by the 68Ga-FAPI/18F-FDG dual-imaging model to be unlikely to achieve a pathologic complete response will be randomly assigned to receive Adebrelimab in combination with nab-paclitaxel and cisplatin of each 3-week cycle for 2 cycles. Participants without a contraindication to surgery will undergo esophagectomy 4 to 6 weeks after the last treatment dose.

06

What researchers measure

Primary outcomes

  1. pCR

    Complete Pathological response, no residual viable tumor cells in the primary tumor or lymph nodes.

    Time frame: One week after surgery

Secondary outcomes

  1. MPR

    Major Pathological Response, the residual tumor cells in the primary tumor were less than 10%.

    Time frame: One week after surgery

  2. R0 resection rate

    Both ends and circumferential margins were negative

    Time frame: One week after surgery

  3. EFS

    Event-free survival (EFS) was assessed by the investigator per RECIST 1.1 and was defined as the time from randomization to the occurrence of a study-defined event.

    Time frame: 3 years after treatment initiation

  4. OS

    Overall survival (OS) was defined as the time from randomization to death from any cause.

    Time frame: 3 years after treatment initiation

  5. safty

    incidence of adverse events and surgical complications during treatment

    Time frame: Within 90 days after treatment completion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Mar 2029, 30 months later.

Of 174 non-industry phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 85. This study's planned 30 months is below that.

Counting every sponsor, half of 198 studies reached it within 52 months; a quarter within 33 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2026
First posted
Aug 18, 2026
StartEst.
Aug 20, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2029
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07770672
Lead sponsor
Tan Lijie
Responsible party
Tan Lijie (chief physician, Shanghai Zhongshan Hospital) — Sponsor-investigator
First posted
Aug 18, 2026
Start date
Aug 20, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Aug 18, 2026

Study contacts

Han Tang
Contact
tang.han@zs-hospital.sh.cn
021-64041990

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1701

Start the discussion